A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia-Reference-Cited by-同舟云学术

A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia

Published:2017 Issue:11 Volume:56 Page:1315-1319
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Tokimatsu Issei¹,Shigemura Katsumi¹²³,Kotaki Tomohiro¹³,Yoshikawa Hiroki⁴,Yamamichi Fukashi⁵,Tomo Tadashi⁶,Arakawa Soichi⁷,Fujisawa Masato²,Kadota Jun-ichi⁴

Affiliation:

1. Department of Infection Prevention and Control, Kobe University Hospital, Japan

2. Department of Urology, Kobe University Graduate School of Medicine, Japan

3. Division of Infectious Diseases, Department of International Health, Kobe University Graduate School of Health Science, Japan

4. Department of Respiratory Medicine and Infectious Diseases, Oita University, Faculty of Medicine, Japan

5. Department of Urology, Hyogo Prefectural Amagasaki General Medical Center, Japan

6. Blood Purification Center, Oita University Hospital, Japan

7. Sanda City Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/56/11/56_56.8369/_pdf

Reference19 articles.

1. 1. Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 118: 29-38, 2005.

2. 2. Edmiston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 48: 1012-1016, 2004.

3. 3. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety: an analysis of 14 years of clinical data. Drugs R D 12: 71-100, 2012.

4. 4. American Theoretic Society, Infectious Disease Society of America. Guideline for management of adults with hospital-acquired, ventilator-associated, and Healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388-416, 2005.

5. 5. Albertson TE, Dean NC, El Solh AA, Gotfried MH, Kaplan C, Niederman MS. Fluoroquinolones in the management of community-acquired pneumonia. Int J Clin Pract 64: 378-388, 2010.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Key Factors in Effective Patient-Tailored Dosing of Fluoroquinolones in Urological Infections: Interindividual Pharmacokinetic and Pharmacodynamic Variability;Antibiotics;2022-05-11

2. Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy;Frontiers in Pharmacology;2020-05-29

3. Moxifloxacin in Chronic Obstructive Pulmonary Disease: Pharmacokinetics and Penetration into Bronchial Secretions in Ward and Intensive Care Unit Patients;Antimicrobial Agents and Chemotherapy;2019-03

4. Moxifloxacin;Reactions Weekly;2017-07